Asset profile
HS-10353
Small molecule
Evidence outlook · lead readout
NCT05195203 · Major Depressive Disorder
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05195203: The study is randomized and double-blind with a placebo comparator, which is a sound design, but its primary measure is safety monitoring rather than depression symptom improvement, and no results have been posted yet.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.